Black Mesa

What Black Mesa does

Black Mesa is a Boston-based technology company founded in 2022 that builds AI-enabled quality assurance tools for pharmaceutical biomanufacturing. Its core product, VERISCAN, is a patent-pending platform that bridges paper-based and electronic batch records by applying computer vision, natural language processing, and machine learning models trained on thousands of batch records to detect documentation errors in real time at the moment of scanning. Each page is fingerprinted with cryptographic hashes and QR codes to prove record integrity, and the platform makes handwritten notes, calculations, and observations searchable across historical batches, addressing the dominant cause of FDA 483 warnings.

The company serves pharmaceutical and biopharmaceutical manufacturers subject to 21 CFR Part 11 regulatory requirements, with particular focus on early-stage drug development organizations still relying on paper-based documentation. VERISCAN is sold via a consultative, enterprise-oriented sales motion anchored by a 'Request Demo' contact mechanism, with pricing not publicly disclosed. Revenue model is recurring platform licensing or subscription alongside implementation support, though no revenue figures are publicly reported.

In January 2026, Black Mesa was awarded ARPA-H funding under the CATALYST program to develop a Good AI Practice (GAIP) framework — an initiative to set standards for AI used in drug development under 21 CFR regulations, with the FDA and NIH as collaborators. The company is led by CEO Charles Fracchia, has 1-10 employees, and previously worked with the Department of Health and Human Services on infrastructure critical to the U.S. medicine supply.

Name

Black Mesa

Legal name

Black Mesa

Website

https://blackmesa.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Black Mesa is a Boston-based technology company that provides VERISCAN, an AI-powered quality assurance platform for pharmaceutical biomanufacturing that digitizes and error-checks paper-based batch records without disrupting existing workflows.

Ownership category

akta.pro rank

Product category

Pharmaceutical Biomanufacturing Quality Assurance Software

NAICS

Software Publishers (5132)

SIC

Services-Testing Laboratories (8734), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs) (HLAGAJAI)

Keywords

• Batch record review
• Biomanufacturing quality assurance
• Pharmaceutical compliance software
• Electronic batch records
• FDA 21 CFR Part 11

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. VERISCAN Platform Licensing/Subscription: VERISCAN is described as a product bridging paper and electronic batch records, suggesting a SaaS or subscription licensing model for biomanufacturing customers. The product is offered alongside implementation support and digital record management services. Revenue is derived from recurring platform fees for AI-enabled batch record review, cryptographic verification, and digital archiving capabilities.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Black Mesa develops and sells VERISCAN, an AI-enabled quality assurance platform for pharmaceutical biomanufacturing that converts paper-based batch records into searchable, error-checked digital records in real time. The product applies machine learning, computer vision, and cryptographic verification to detect missing signatures, calculation errors, and incomplete fields at the moment of scanning, while keeping manufacturers' existing paper workflows intact. The company is also developing the Good AI Practice (GAIP) framework under ARPA-H funding to establish standards for AI use in drug development under FDA 21 CFR regulations.

Product overview

Black Mesa offers a single core product called VERISCAN - an AI-powered batch record review platform designed specifically for biomanufacturing. VERISCAN bridges the gap between traditional paper-based documentation and electronic batch records, allowing manufacturers to maintain their existing paper workflows while gaining digital benefits including real-time error detection, searchable records, and compliance reporting. The company is also developing a Good AI Practice (GAIP) framework in partnership with ARPA-H to establish standards for responsible AI use in drug development.

Differentiator

Problem solved

Functional benefit

Brands

• VERISCAN: AI-powered batch record review platform that bridges the gap between traditional paper and electronic batch records. Uses cryptography, machine learning, and data analytics to streamline quality review without requiring customers to switch to a fully digital system.

Products and services

• VERISCAN AI-enabled quality assurance platform for pharmaceutical biomanufacturing that transforms paper batch records into searchable, error-checked digital records using cryptography, machine learning, and data analytics. Catches missing signatures, calculation errors, and incomplete fields at the moment of scanning, provides cryptographic record integrity with QR-coded fingerprints, makes handwriting searchable, and generates compliance reports for FDA 21 CFR Part 11 environments. Targeted at pharmaceutical and biopharmaceutical manufacturers operating paper-based or hybrid batch record systems.

Quantifiable outcome

• 8% of FDA 483 warnings are from documentation and data integrity errors
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• ARPA-H (Advanced Research Projects Agency for Health)flagshipStrategic or Co-development Partner · 20 January 2026Black Mesa was awarded funding from ARPA-H to develop a Good AI Practice (GAIP) framework under the CATALYST (Computational ADME-Tox and Physiology Analysis for Safer Therapeutics) program. The GAIP framework will create methods ensuring AI models, datasets, and infrastructure used in drug predictions meet high-quality, traceable, and regulatory-compliant standards under 21 CFR regulations. This is a flagship partnership given its direct alignment with Black Mesa's core product strategy and the prestige of ARPA-H funding.
• Department of Health and Human Services (HHS)coreStrategic or Co-development Partner · 20 January 2026Black Mesa built on prior work with HHS where they 'defended billions of dollars of infrastructure critical to the American medicine cabinet.' This prior engagement laid the foundation for the current ARPA-H GAIP project, indicating an established relationship with federal health agencies focused on pharmaceutical infrastructure protection.
• FDA (Food and Drug Administration)coreStrategic or Co-development Partner · 20 January 2026FDA is referenced as a key government partner within the ARPA-H CATALYST program ecosystem. Andy Kilianski (ARPA-H Acting Deputy Director) stated that CATALYST's tools will be developed in collaboration with the FDA, NIH, and partners across government, academia, and industry. The GAIP framework specifically addresses 21 CFR regulatory compliance requirements enforced by the FDA.
• NIH (National Institutes of Health)minorStrategic or Co-development Partner · 20 January 2026NIH is referenced as a partner within the ARPA-H CATALYST program alongside the FDA and collaborators across government, academia, and industry. While mentioned as part of the broader CATALYST initiative, NIH's role appears secondary to the FDA in the context of Black Mesa's GAIP framework.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Tulip Interfaces: Frontline operations and quality apps platform for manufacturers, including regulated industries. Comparable because both bring digital, app-based capabilities into paper-heavy manufacturing and quality workflows where shop-floor documentation is the bottleneck.
• TetraScience: Scientific data cloud and AI data platform purpose-built for life sciences R&D and manufacturing. Comparable because both seek to unlock latent data from paper-based and unstructured pharma workflows and route it into analytics, AI, and compliance systems.
• Dot Compliance: AI-enabled quality management software for life sciences on the Salesforce platform, including document control and quality workflows. Comparable because both apply AI to GxP quality and documentation problems for pharma and biotech manufacturers.
• Polaris Compliance: Quality and compliance software provider serving life sciences manufacturers with document, training, and audit capabilities. Comparable because both focus on streamlining GxP documentation and audit readiness for small and mid-sized biopharma.

Direct peers

• Qualio: Cloud-native eQMS for life sciences startups and mid-market manufacturers, including document control and batch record modules. Comparable because both sell to small and mid-sized biopharma manufacturers seeking modern, AI-friendly quality tooling.
• Kneat Solutions: Electronic validation and logbook platform purpose-built for regulated life sciences environments. Comparable because both target paper-to-digital transitions in GxP documentation workflows that include batch records and compliance audit trails.
• ValGenesis: Lifecycle and validation management software for life sciences, focused on electronic validation, logbooks, and compliance documentation. Comparable because both compete for regulated documentation and process integrity workflows in biomanufacturing.
• MasterControl: Provider of eQMS, document control, and batch record software for life sciences manufacturers. Directly comparable to VERISCAN because both target GxP-compliant quality and documentation workflows in pharmaceutical and biotech manufacturing.

Broad incumbents

• Veeva Systems: Dominant cloud software provider for life sciences, offering Vault Quality, Vault Manufacturing, and CTMS suites that include document management and batch record capabilities for biopharma. Comparable because Veeva is the incumbent platform that biomanufacturers often already use for regulated document and quality workflows.
• LabVantage Solutions: LIMS and laboratory informatics platform used by pharma manufacturers to manage batch records, quality data, and compliance. Comparable because both serve regulated biomanufacturing documentation and quality use cases, even though LabVantage sits more on the LIMS side.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/black-mesa-technology

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Black Mesa